IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 12.6 SEK -1.95%
Market Cap: 652.5m SEK
Have any thoughts about
IRLAB Therapeutics AB?
Write Note

IRLAB Therapeutics AB
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

IRLAB Therapeutics AB
Capital Expenditures Peer Comparison

Comparables:
CALTX
CAMX
S
SECARE
MOB
I
FLERIE

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
IRLAB Therapeutics AB
STO:IRLAB A
Capital Expenditures
-kr293k
CAGR 3-Years
9%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Capital Expenditures
-kr7.3m
CAGR 3-Years
-26%
CAGR 5-Years
14%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Capital Expenditures
-kr62.9m
CAGR 3-Years
-141%
CAGR 5-Years
-57%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is IRLAB Therapeutics AB's Capital Expenditures?
Capital Expenditures
-293k SEK

Based on the financial report for Dec 31, 2023, IRLAB Therapeutics AB's Capital Expenditures amounts to -293k SEK.

What is IRLAB Therapeutics AB's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
23%

Over the last year, the Capital Expenditures growth was 90%. The average annual Capital Expenditures growth rates for IRLAB Therapeutics AB have been 9% over the past three years , 23% over the past five years .

Back to Top